Pharma and life sciences · eClinical software
You hear of the trial after the stack is chosen.
You sell EDC, eCOA, eConsent or RTSM to sponsors and their CROs. A US trial can register up to 21 days after first patient in, once the CRO and systems are chosen. Win one study, and the next protocol starts a new selection.
- Typical deal
- €15–250k a year Illustrative
- Biotech sales cycle
- 1–9 months Illustrative
- Buying panel
- 3–5 people plus the CRO Illustrative
Updated 5 October 2026 · Based on Panelhop research, October 2026
At a clinical-stage biotech sponsor3–5 people Illustrative
The short answer
How do eClinical vendors sell to biotech sponsors and CROs?
eClinical vendors win deals with biopharma and medtech companies at the sponsor’s study decision, soon after a financing round or phase move, and often inside a CRO’s bid. The products are EDC, eCOA, eConsent and RTSM, sold to sponsors and their CROs. At clinical-stage biotech, clinical operations chooses and the CEO and finance approve, over 1–9 months by our estimate.
eClinical software · How a deal really moves
The stack was chosen before you called. Say yes, and QA audits you late. The next study starts over. The same sponsor, reached at the round. The audit opens at the first meeting. The next study is watched.
One clinical-stage sponsor, 3–5 people plus its CRO, and an estimated 1–9 months from first signal to signature.
What opens a deal
- Series A, B or C closes: Funding
- Phase 3 start: Milestone
- New protocol or CRO bid: Contract
- ICH E6(R3) Annex 2 in force: Regulation · EU
- Acquisition closes: Consolidation
- New head of clinical ops: Leadership
Signal Desk · weekly: In-market accounts, scored and mapped
Your buyer and who decides
A clinical-stage sponsor
Biotech, pharma or medtech, and their CROs
211 new trial applications a month in CTIS
Panel Check · coverage baselined
- Clinical operations lead, can Veto: A system that slows site start-up or mid-study changes.
- CEO, COO or CFO, can Veto: Spend that does not move a trial milestone.
- QA and validation, can Veto: A validation gap an inspector finds after database lock.
- IT and security, can Veto: Patient data held where the DPA does not allow it.
- Clinical data manager: Losing data or audit trail when a study changes systems.
- CRO systems lead: Recommending a system its staff cannot run.
How the deal moves
Targeting Typical time: 2–8 weeks
- Where it stalls
- You find the trial once its stack is chosen
- With Panelhop: Signal Desk
- Sponsors with a fresh round or phase move, scored, in your CRM weekly
CRO bid
- Where it stalls
- The CRO brings its own stack to the bid
- With Panelhop: Signal Desk
- Sponsor and CRO accounts mapped together, bid awards tracked as triggers
First meeting
Evaluation Typical time: 1–3 months
- Where it stalls
- The data manager loves it and owns no budget
- With Panelhop: Leak Fix
- Clinical operations, QA, IT and finance mapped, with coverage tracked
Vendor audit
- Where it stalls
- QA’s audit starts as first patient in nears
- With Panelhop: Leak Fix
- Supplier qualification opened at the first meeting, its days tracked
Contract Typical time: 1–3 months
Study build
Expansion
- Where it stalls
- One study won, and the next is a new pitch
- With Panelhop: Panel Ops
- Each sponsor’s coming studies worked as expansion triggers, monthly
Panel Ops · monthly: Scores and plays tuned against the baseline
Illustrative Source: Stages, seats, triggers and stalls from Panelhop research, October 2026; ACT EU (European Commission, EMA and HMA); the services as described on the Services page. Note: Durations, panel sizes and cycle lengths are Panelhop estimates from our research, not measurements.
At a glance
| Typical deal | €15–250k a year Illustrative |
|---|---|
| Biotech sales cycle | 1–9 months Illustrative |
| Buying panel | 3–5 people plus the CRO Illustrative |
| How deals start | A financing round or study decision, then a demo request |
Source: Panelhop research, October 2026. Note: Values marked Illustrative are Panelhop estimates from our research, not measurements.
eClinical leaks trace back to the sponsor’s study timeline.
Why do eClinical deals with sponsors and CROs stall?
eClinical deals stall where the vendor arrives after the study decision, misses the CRO, meets QA late or wins one study and stops. A vendor can follow each sponsor’s study timeline and see these leaks coming.
Where the pipeline leaks: 5 points across 8 stages.
Registry lists point at studies already decided
- What you see
- Prospects say they chose a vendor for this study last quarter.
- Why it happens
- Lists come from trial registries and company type. In our analysis of life sciences vendors’ websites, none of the 13 vendors segments by clinical phase.
Stage Targeting
Lose one study and the next goes uncontested
- What you see
- The competitor wins the next study at the same sponsor without a contest.
- Why it happens
- Closed-lost records hold no study, phase or contract-end fields, so the sponsor’s next protocol never becomes a trigger.
Stage Targeting
‘Our CRO handles it’ ends the sponsor deal
- What you see
- Biotech prospects say their CRO handles it, and wins swing with CRO bid outcomes.
- Why it happens
- Sponsor and CRO accounts are not mapped together and bid awards are not tracked. In our analysis of vendors’ websites, 2 of the 4 mid-market clinical trial software vendors use CRO partnerships as a route to sponsors.
Stage CRO bid
The supplier audit collides with first patient in
- What you see
- Close dates slip while QA audits the vendor, and the first patient in date comes under pressure.
- Why it happens
- Supplier qualification is not a stage in the CRM or forecast. In our analysis of vendors’ websites, late GxP qualification was a likely bottleneck for all 4 mid-market clinical trial software vendors.
Stage Vendor audit
Every new protocol is a new pitch
- What you see
- The logo count grows while revenue per sponsor stays flat.
- Why it happens
- Relationships sit with one study team and pricing is per study. In our analysis of vendors’ websites, landing one study without expanding was a likely bottleneck for 3 of the 4 mid-market clinical trial software vendors.
Stage Expansion
The sponsor’s next study start opens the window.
What makes a sponsor buy new eClinical systems?
Sponsors buy eClinical systems when money arrives, a programme moves phase, a new protocol is filed or a rule changes trial design. Each event can be dated against the sponsor’s next study start.
The 6 events that open or close the window for a deal.
Funding
Financing round closes
- What happens
- A clinical-stage biotech closes a Series A, B or C round that names a trial start.
- Where to spot it
- Financing trackers, company press releases and the BioIndustry Association’s quarterly UK data.
- Window
- Purchases tend to follow 1–6 months after close, tied to the next study start.
Budget cycle
Move from Phase 2 to Phase 3
- What happens
- A programme moves into a larger trial with more sites, more countries and patient-reported outcomes.
- Where to spot it
- CTIS, company press releases and investor decks.
- Window
- Opens 6–12 months before the milestone.
Contract
New trial application or CRO bid
- What happens
- A sponsor files a new protocol, or a CRO asks technology partners to support a bid defence.
- Where to spot it
- New trials on the CTIS public portal, published once a decision is taken, and CRO partner channels.
- Window
- Opens 1–4 months before first patient in.
Regulation
ICH E6(R3) Annex 2
- What happens
- Annex 2 covers decentralised and pragmatic trials and trials that use real-world data, so sponsors and CROs review data flows, validation and vendor oversight.
- Where to spot it
- EMA’s ICH E6 page and sponsors’ study quality plans.
- Window
- Takes effect in the EU on 15 January 2027; reviews run 3–6 months before and through 2027 study starts.
Consolidation
Acquisition closes
- What happens
- An acquired sponsor moves new studies to the acquirer’s preferred systems, or keeps its own.
- Where to spot it
- M&A trackers and closing notices in company filings.
- Window
- Purchases follow 0–12 months after close.
Leadership
New head of clinical operations
- What happens
- A new VP of clinical operations or data management reviews the CRO and technology choices.
- Where to spot it
- Industry appointment roundups and job changes at target sponsors.
- Window
- Often opens in the new leader’s first months, as they review the CRO and technology choices.
Clinical operations chooses, often inside the CRO’s bid.
Who decides on EDC and eCOA at a biotech sponsor?
At a clinical-stage biotech, the head of clinical operations usually chooses the eClinical stack, and the CEO and finance approve the spend. In CRO-run studies, the CRO’s clinical systems team often brings its own tools into the bid, so it shapes the choice from outside. At a small sponsor, the same person often holds several of these seats.
At a clinical-stage biotech sponsor, 3–5 people sit on the panel and 5 seats can stop the deal.
At a clinical-stage biotech sponsor: 3–5 people
Clinical operations lead
Can Veto
VP Clinical Operations · Clinical Study Manager
- Cares about
- First patient in on the date the board was promised.
- Worries about
- A system that slows site start-up or mid-study changes.
Clinical data management
Head of Data Management · Clinical Data Manager
- Cares about
- Clean data, quick mid-study builds and an on-time database lock.
- Worries about
- Losing data or audit trail when a study changes systems.
CEO or COO
Can Veto
CEO · COO
- Cares about
- Spending financing proceeds on what moves the next readout.
- Worries about
- Spend that does not move a trial milestone.
CRO clinical systems lead
CRO Senior Director Clinical Systems · Director Vendor Management (CRO)
- Cares about
- A stack its teams and sites already know, so the bid stays competitive.
- Worries about
- Recommending a system its staff cannot run.
QA and computerised system validation
Can Veto
Head of Quality Assurance · CSV Lead
- Cares about
- Part 11 and Annex 11 evidence and a supplier audit before go-live.
- Worries about
- A validation gap an inspector finds after database lock.
IT and information security
Can Veto
System Owner · IT Security Risk Manager
- Cares about
- Hosting region, access control and SOC 2 Type II or ISO 27001 evidence.
- Worries about
- Patient data held where the DPA does not allow it.
Finance
Can Veto
CFO · Controller
- Cares about
- A per-study cost that fits the runway, with add-ons and validation priced upfront.
- Worries about
- Add-ons, validation reports and annual increases that outgrow the budget.
You sell the trial’s data backbone, study by study.
What do eClinical vendors sell, and to whom?
eClinical vendors sell the systems that capture trial data, randomise participants and record consent for sponsors and CROs. The mid-market clinical trial software vendors we analysed pitch quick study builds and built-in validation against the enterprise suites, and some price per study or project.
What vendors of this type sell
- Electronic data capture (EDC) and clinical data management
- eCOA and ePRO for clinician- and patient-reported outcomes
- eConsent for site-based and remote informed consent
- Randomisation and trial supply management (RTSM or IRT)
- Clinical data platforms and data management services
- CTMS and eTMF for study management and the trial master file
Which biopharma and medtech companies buy it
- Clinical-stage biotech sponsors after a financing round
- Mid-size and top-tier pharma sponsors running drug studies
- Medtech sponsors running device studies
- CROs choosing technology partners for their bids
eClinical deals turn on the round and the bid.
How does an eClinical deal move at a biotech sponsor?
An eClinical deal moves from a financing round or study decision through the CRO bid, demos and a supplier audit to contract and study build. By our estimate, clinical-stage biotechs decide in 1–9 months, so the first patient in date compresses these stages and the audit often runs alongside the contract. Durations show the buyer’s side; the longer ones apply at mid-size and larger sponsors.
Stage by stage: what you do, what the biopharma or medtech company does, and what changes at the 5 stages where deals stall.
| Stage | What you do | What the biopharma or medtech company does | Today | With Panelhop |
|---|---|---|---|---|
| Targeting Typical time: 2–8 weeks | Lists sponsors by company type and watches trial registries. | Closes a round or decides to run a study, then lines up a CRO, sites and systems. | Sponsors are found once their trial is registered. Stalls: The registry entry comes after the choice. US registration can come up to 21 days after the first participant enrols, so a vendor working from registries arrives once the CRO and systems are chosen. | Each week, sponsors with a fresh round, a phase move or a new clinical leader arrive in your CRM, scored, with the signal that fired. Signal Desk In-market accounts, weekly |
| CRO bid | Courts CROs as partners, or waits for the sponsor to ask. | Asks CROs to bid; the winning CRO often brings its preferred EDC, RTSM or eCOA. | The CRO’s preferred stack wins without a contest. Stalls: The CRO picks the stack. At small and mid-size sponsors the CRO’s clinical systems team often brings its own tools into the bid, so the sponsor may never run its own selection. | Sponsor and CRO accounts are mapped together, study starts and bid awards arrive as triggers, and the rep is briefed on both sides before the CRO’s choice becomes the sponsor’s. Signal Desk In-market accounts, weekly |
| First meeting | Answers a demo request from a data manager or study manager. | Data management and clinical operations ask for a hands-on demo and a sandbox. | Demo requests wait in a queue for a rep. | Demo requests are enriched, matched to the account and routed in minutes, with an SLA and escalation. Leak Fix We build the fixes |
| Evaluation Typical time: 1–3 months, then 2–6 weeks of references | Runs scripted demos and lines up references from a sponsor ‘like us’. | Scores usability for sites, sponsors and CROs, then calls peers and checks benchmark ratings. | One data manager carries the deal. Stalls: The champion holds no budget. A data manager likes the build tools, but clinical operations, QA and finance decide, and they meet the vendor late. | A role map per tier covers clinical operations, QA, IT and finance, with missing roles enriched and coverage tracked per account. Leak Fix We build the fixes |
| Vendor audit Typical time: 2–6 months at mid-size and larger sponsors | Answers the QA questionnaire and hosts a supplier audit, often after the verbal yes. | QA audits the vendor as a GxP supplier; IT and security review hosting and access. | QA first sees you after the verbal yes. Stalls: The audit starts after the choice. QA’s supplier audit and the security questionnaire begin once the study team has chosen, which puts the first patient in date at risk. | Supplier qualification becomes a stage with exit criteria, opened at the first meeting, and its days are tracked in the forecast. Leak Fix We build the fixes |
| Contract Typical time: 1–3 months, often alongside the audit | Prices the study build, add-ons and the validation package. | Procurement, legal and finance agree the MSA, work order, DPA and quality agreement. | Signature drifts away from the study start. | A mutual action plan dates the legal, QA and finance steps back from the first patient in date. Leak Fix We build the fixes |
| Study build | Builds and validates the database, eCOA and randomisation, then trains sites. | Tests and accepts the build before first patient in. | What sales promised about the build lives in one rep’s head. | A handoff document built from the deal records what was promised about build time, validation and site training. Leak Fix We build the fixes |
| Expansion | Waits for the sponsor to come back with the next protocol. | Chooses again at the next study, phase or portfolio decision. | The next study waits for the sponsor to call. Stalls: One study, then silence. Pricing per study with no portfolio agreement makes every new protocol a new selection, often won by whoever is already in the room. | Panel Ops operates the expansion triggers on each sponsor’s coming studies with your team, reviews signals weekly and reports against the baseline every month. Panel Ops We run it monthly |
Reach the sponsor at the round, not the registry.
How does Panelhop help eClinical vendors sell to sponsors and CROs?
Panelhop helps eClinical vendors reach sponsors at the financing round and the phase move. Signal Desk (in-market accounts, weekly), Leak Fix (we build the fixes) and Panel Ops (we run it monthly) work the stages that leak. Each is measured against a baseline from a Panel Check (GTM audit).
What we baseline and report
- Days from a financing round or phase move to your rep’s first touch, against the baseline
- Open deals with clinical operations, QA and finance engaged, against the baseline
- Studies per sponsor account, against the baseline
Other vendor types in pharma and life sciences.
What other vendors sell to biopharma and medtech companies?
The same biopharma and medtech companies buy from these vendor types too, through different panels and pipelines.
- Vendor type
eQMS and quality management software
Cloud eQMS for document control, training, CAPA, audits and supplier quality, sold to device makers, biotechs, pharma sites and CDMOs.
Read the pipeline - Vendor type
Regulatory information and pharmacovigilance software
RIM, submission, UDI and safety database software sold to regulatory affairs and drug safety teams at biopharma and medtech companies.
Read the pipeline - Vendor type
Lab and manufacturing software
LIMS, ELN, MES and electronic batch record software sold to QC labs, manufacturing sites and CDMOs in pharma, biotech and medtech.
Read the pipeline - Vendor type
Commercial data and HCP intelligence
HCP, site, patient and access data and analytics for biopharma commercial, medical affairs, market access and patient services teams.
Read the pipeline
The words your buyers use, defined.
What do terms like “EDC” and “eConsent” mean?
Plain definitions of the terms that come up when you sell eClinical software to biopharma and medtech companies.
- EDC
- Electronic data capture: the system trial sites use to enter data into electronic case report forms, with edit checks and an audit trail. Sponsors and CROs build a database per study.
- eConsent
- Electronic informed consent: participants review and sign trial consent on a device, on site or remotely, with versions and signatures kept for inspection.
- eCOA and ePRO
- Electronic clinical outcome assessment: patients, clinicians or caregivers record outcomes on a device or app. ePRO is the patient-reported part, common in larger and decentralised trials.
- RTSM (IRT)
- Randomisation and trial supply management, also called interactive response technology: the system that assigns participants to treatment arms and manages drug supply to sites.
- CRO bid defence
- The meeting where a CRO presents its proposal, team and technology to a sponsor before the award. A technology vendor the CRO brings along can win the study inside the bid.
- First patient in
- The date the first participant is enrolled in a trial. eClinical systems must be built, validated and live before it, so the date sets the vendor’s real deadline.
Answers before your next biopharma or medtech company deal.
What do vendors of eClinical software ask about selling to biopharma and medtech companies?
How soon after a Series B do biotechs buy clinical trial software?
Biotechs tend to buy clinical trial software once a financing round closes, typically 1–6 months after close and tied to the next study start, by our estimate. The CRO, sites and systems are usually chosen before the trial is registered. US registration can come up to 21 days after the first participant enrols. eClinical vendors should treat the financing round as the trigger.
Why do biotech sponsors say their CRO handles the EDC?
Biotech sponsors say their CRO handles the EDC because the CRO often brings its preferred EDC, RTSM or eCOA into its bid. In those studies the sponsor never runs its own selection. eClinical vendors that map sponsor and CRO accounts together, track bid awards and join CRO bid defence meetings are in the conversation before the CRO’s choice becomes the sponsor’s.
How do eClinical vendors get a meeting with a VP of clinical operations?
eClinical vendors get meetings with a VP of clinical operations at a biotech sponsor by writing about that sponsor’s next study, soon after a financing round or phase move, rather than about the product. Clinical operations leaders research before they talk to suppliers and ignore generic sequences. A short note from a named rep tied to the coming study start tends to get further. So do introductions through the sponsor’s CRO or a consultant and peer sessions at DIA or SCDM.
How long does it take to sell an EDC system to a biotech or pharma sponsor?
By our estimate, selling EDC to a clinical-stage biotech takes 1–9 months, typically about 4 months, because the trial start date sets the deadline. Enterprise EDC and RTSM deals at top-tier biopharma take an estimated 6–24 months. At mid-size and larger sponsors, a GxP supplier audit of an estimated 2–6 months sits inside the cycle. At a clinical-stage biotech, the audit has to fit before first patient in.
Can trial registries be used for eClinical sales prospecting?
Trial registries help eClinical prospecting, but they arrive late. US registration can come up to 21 days after the first participant enrols, by which time the CRO and systems are chosen. EU trials must be authorised through CTIS before they start, and sponsors submitted an average of 211 new trial applications a month in Q4 2025. Earlier signals are financing rounds, phase moves and new clinical operations leaders.
Who decides on EDC selection at a biotech sponsor?
At a clinical-stage biotech sponsor, the head of clinical operations usually chooses the EDC, with clinical data management shaping the requirements. The CEO and finance approve the spend, and QA, IT and security can each stop the deal. In CRO-run studies, the CRO’s clinical systems team often brings its own EDC into the bid. By our estimate, the group has 3–5 people, plus the CRO’s team.
Where the numbers come from.
Sources
Sourced figures link to their source below. Figures marked Illustrative, and figures given as estimates, are inferred from Panelhop research. Vendors appear only as types, never by name.
- Electronic Code of Federal Regulations (eCFR), US Office of the Federal Register, 42 CFR § 11.24: When must clinical trial registration information be submitted? (2026)
- ACT EU (European Commission, EMA and HMA), Monitoring the European clinical trials environment, October–December 2025 (2026)
- BioIndustry Association, UK biotech venture investment reaches five-year high in Q2 2026, driven by record private financing (2026)
- European Medicines Agency, ICH E6 Good clinical practice: scientific guideline (2026)
- Panelhop research, October 2026: our analysis of the vendors, buying panels, pipelines and triggers for eClinical software in pharma and life sciences, from public sources. Vendor names are not published.
Find where your pipeline to biopharma and medtech companies leaks.
